ArticleClinical and translational gastroenterology2025
Burden of Metabolic Bone Disease in Patients with Immunoglobulin G4-Related Disease With and Without Autoimmune Pancreatitis: A Cross-Sectional Study.
Article in Clinical and translational gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
introductionPatients with immunoglobulin G4-related disease (IgG4-RD) have risk factors of metabolic bone disease (MBD), yet data are lacking on the prevalence of MBD in IgG4-RD. We assessed screening frequency and prevalence of MBD in patients with IgG4-RD with and without pancreatic involvement.
methodsUsing an IgG4-RD registry, we extracted details from medical records related to MBD in patients who actively followed in our system. Living patients with contact information available were invited to complete surveys detailing MBD and associated characteristics.
resultsSeventy patients met criteria for medical records review (n = 17 with pancreatic involvement). Fifty-one percent had taken proton-pump inhibitors, and 30% had investigator-determined MBD. Compared with the US population, the age-standardized prevalence of osteoporosis in the IgG4-RD cohort was higher among both female patients (28.1% vs 19.6%, P = 0.40) and male patients (8.3% vs 4.4%, P = 0.48), though this did not achieve statistical significance. Mean T-scores at all sites were numerically lower in patients with pancreatic involvement than those without (all P > 0.1). In patient-reported data (n = 105), despite 62% of patients reporting ≥3 months of glucocorticoid exposure, only 36% had a dual-energy x-ray absorptiometry performed. Of 15 patients for whom pharmacologic MBD treatment was recommended, 8 (53%) reported adherence to this recommendation. DISCUSSION: The burden of MBD and its risk factors is high in patients with IgG4-RD, yet screening and treatment is low. Although our study was underpowered to detect statistical differences, there may be a greater burden of MBD in patients with pancreatic involvement. Screening and treatment of MBD should be emphasized in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.